Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor (Q38078285)

28 August 2017

1 reference

title

Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor (English)

1 reference

28 August 2017

1 reference

Hui Zhu

1

1 reference

PubMed ID

23371447

28 August 2017

Jorge A Garcia

series ordinal

2

1 reference

28 August 2017

1 April 2013

1 reference

28 August 2017

Current Oncology Reports

1 reference

28 August 2017

15

1 reference

28 August 2017

105-112

1 reference

28 August 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-013-0300-1

28 August 2017

0 references

cites work

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Endocrine treatment in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

The androgen axis in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Mechanisms of androgen receptor activation and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Steroid receptor interactions with heat shock protein and immunophilin chaperones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

The development of androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

The program of androgen-responsive genes in neoplastic prostate epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Adrenal steroids in human prostatic cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Interleukin-6 regulation of prostate cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Role of Chemokines and Chemokine Receptors in Prostate Cancer Development and Progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Interaction of IGF signaling and the androgen receptor in prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Targeting the PI3K/AKT pathway for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Molecular genetics and epidemiology of prostate carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Expression, structure, and function of androgen receptor in advanced prostatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Expression and enzymatic activity of the P450c17 gene in human adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Pharmacologic alteration of steroid hormone functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Gynecomastia with ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Effects of high dose ketoconazole therapy on the main plasma testicular and adrenal steroids in previously untreated prostatic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Ketoconazole and liarozole in the treatment of advanced prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Longitudinal study of depressive symptoms in patients with metastatic gastrointestinal and lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

ANDROGEN RECEPTOR GENE AMPLIFICATION AT PRIMARY PROGRESSION PREDICTS RESPONSE TO COMBINED ANDROGEN BLOCKADE AS SECOND LINE THERAPY FOR ADVANCED PROSTATE CANCER

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-013-0300-1

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

21 January 2018

1 reference

12 December 2020

Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence

1 reference

12 December 2020

EFFECT OF ORCHIECTOMY AND IRRADIATION ON CANCER OF THE PROSTATE

1 reference

12 December 2020

Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor

1 reference

12 December 2020

Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

1 reference

12 December 2020

Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process

1 reference

12 December 2020

Androgen receptor defects: historical, clinical, and molecular perspectives

1 reference

12 December 2020

Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal

1 reference

12 December 2020

Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist

1 reference

12 December 2020

Pharmacology and biochemistry of some amphenone analogues and other adrenal cortical inhibitors

1 reference

12 December 2020

Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer

1 reference

12 December 2020

Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping

1 reference

12 December 2020

Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer

1 reference

12 December 2020

Ketoconazole therapy for advanced prostate cancer

1 reference

12 December 2020

Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.

1 reference

12 December 2020

Androgen receptor mutations in prostate cancer.

1 reference

12 December 2020

Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.

1 reference

12 December 2020

Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis

1 reference

12 December 2020

Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers

1 reference

12 December 2020

Steroidal androgen biosynthesis inhibitors

1 reference

12 December 2020

Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.

1 reference

12 December 2020

Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade

1 reference

12 December 2020

10.1007/S11912-013-0300-1

Identifiers

DOI

1 reference

PubMed ID

23371447

Dimensions Publication ID

28 August 2017

0 references

1 reference

PubMed ID

23371447